Revolution Medicine shares are trading higher. The company announced that it has begun treating patients in its Phase 3 clinical trial of zoldonrasib in combination with pembrolizumab plus chemotherapy to treat metastatic non-squamous non-small cell lung cancer.
Share
Why It Matters
Revolution Medicine started testing a new drug combination on real patients. Watch for updates on whether the treatment works well and is safe.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.